Use access key #2 to skip to page content.
$0.16 0.05 (45.45%)
11/21/2008 3:30 PM

Accentia Biopharmaceuticals, Inc. (ABPI)

CAPS Rating:
**

A biopharmaceutical company focused on the development & commercialization of late-stage, targeted therapeutic clinical products in the areas of respiratory disease &, through its publicly-traded subsidiary, Biovest International Inc., oncology.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

ABPI doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

37 Outperforms
6 Underperforms
 

All-Stars

5 Outperforms
3 Underperforms
 

Members bullish on ABPI are also bullish on:

Members bearish on ABPI are also bearish on:

Ticker Tags

Biotechnology (230), Medical Laboratories & Research (4), Micro Cap (5043)
Suggest a tag

Accentia Biopharmaceuticals, Inc. At A Glance

Current Price: $0.16
Last Trade Time: 11/21/2008 3:30 PM
Open: $0.11
Previous Close: $0.11
Daily Range: $0.11 - $0.16
52-Week Range: $0.21 - $3.39
Volume: 163,285
Market Cap: $10.61M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

ABPI VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for ABPI

More Headlines...

Top Bull Pitch

Recs

1

Accentia Biopharmaceuticals, Inc. (ABPI)

Avatar gingerlade (< 20) Submitted: 12/28/07 8:09 PM

The company has a few blockbuster biopharmaceuticals in the pipeline awaiting


fast track and FDA approval...SinuNase (BDSI)and


Revimmune for 80 autoimmune diseases focusing


for now on relapse-remit MS....and a vaccine


for Hodgkins Lymphoma and a Biovac...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 8 :   1 2 Next »

Recs

0

 (ABPI)

Avatar binx007 (< 20) Submitted: 3/03/08 5:09 PM : Outperform Start Price: $2.43 ABPI Score: -49.50

I am bullish on this spec play. I think they are going to have some good results for us this month and after that, the SKY is the limit. Hold on to your boot straps. The down side is so small it is hard not to love the opportunity to win BIG here.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ABPI)

Avatar maggioli (< 20) Submitted: 1/07/08 9:00 PM : Outperform Start Price: $2.60 ABPI Score: -47.22

The CEO has just given a resounding forward statement, if you wait to long you could miss the boat. If they get FDA approval on all three phase three products the sky is the limit. Buy now or cry later.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ABPI)

Avatar steelpoker (< 20) Submitted: 1/02/08 5:27 PM : Outperform Start Price: $3.25 ABPI Score: -47.41

Going Phase 3 x 3.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (ABPI)

Avatar gingerlade (< 20) Submitted: 12/28/07 8:09 PM : Outperform Start Price: $3.14 ABPI Score: -46.46

The company has a few blockbuster biopharmaceuticals in the pipeline awaiting


fast track and FDA approval...SinuNase (BDSI)and


Revimmune for 80 autoimmune diseases focusing


for now on relapse-remit MS....and a vaccine


for Hodgkins Lymphoma and a Biovac machine


to administer this on fast track....the


vaccine is being put out by BVTI a subsidiary


of APBI....Great potential this stock....of


course this is my humble opinion....as always


one must do their own research into this...


but once you do...you will be flabbergasted


at the potential of these multi-billion


dollar blockbusters if they pass FDA approval...Awesome promise....

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ABPI)

Avatar myersfield (< 20) Submitted: 9/20/07 2:36 PM : Outperform Start Price: $2.68 ABPI Score: -43.73

ABPI is in 2 phase 3 trials and I believe in success.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 8 :   1 2 Next »

Wall Street

picks per page. CHANGE

Sorry, no results found.

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

Sponsored Links